Younger cancer survivors were more likely than their older peers to start alcohol use disorder treatment within 1 year of diagnosis. Less than 15% of cancer survivors diagnosed with alcohol use ...

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.

Pediatric patients with diffuse midline gliomas may have better outcomes if they have a more diverse gut microbiome.

The FDA has granted de novo authorization to CLAIRITY BREAST, a platform that uses AI to help predict a woman's risk of breast cancer.

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.

(HealthDay News) — Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published in JAMA Oncology.

Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

The US Food and Drug Administration (FDA) has expanded the approved use of Nubeqa (darolutamide) for patients with metastatic castration-sensitive prostate cancer (mCSPC). The drug is now approved for ...

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

The number of cancer survivors in the United States reached 18.6 million as of January 1 this year and is projected to exceed 22 million by 2035.

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.